Articles published by Genmab A/S

< Previous 1 2 Next >
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB PFE
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
Genmab Announces Financial Results for the First Nine Months of 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via GlobeNewswire
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
From Genmab A/S
Via Business Wire
Tickers GMAB SGEN
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
From Genmab A/S
Via GlobeNewswire
Genmab Announces Financial Results for the First Half of 2023
From Genmab A/S
Via GlobeNewswire
Genmab Updates 2023 Financial Guidance
From Genmab A/S
Via GlobeNewswire
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
From Genmab A/S
Via GlobeNewswire
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via GlobeNewswire
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
Tickers GMAB
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via GlobeNewswire
Genmab Announces Financial Results for the First Quarter of 2023
From Genmab A/S
Via GlobeNewswire
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
From Genmab A/S
Via GlobeNewswire
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
From Genmab A/S
Via GlobeNewswire
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
From Genmab A/S
Via GlobeNewswire
Genmab Announces Initiation of Share Buy-Back Program
From Genmab A/S
Via GlobeNewswire
Genmab Publishes 2022 Annual Report
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
From Genmab A/S
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.